Physician profile
Mark Rosing
NPI 1639198476
$2,773.34
in general payments reported to CMS, 2019-2025
20 companies · $653 in 2025
The $653 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $760 · 2021: $178 · 2022: $230 · 2023: $224 · 2024: $97.12 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $759.34 | 2019-2020 | |
| Fujirebio Diagnostics, Incorporated | $350.00 | 2019 | |
| Sumitomo Pharma America, INC. | $190.63 | 2023-2025 | Gemtesa, Myfembree |
| Astellas Pharma US INC | $183.65 | 2023-2025 | Veozah |
| Daiichi Sankyo INC. | $164.09 | 2021-2023 | Injectafer |
| Coopersurgical, INC. | $163.74 | 2019-2024 | Sos |
| Abbvie INC. | $148.28 | 2019-2023 | Liletta |
| Viiv Healthcare Company | $125.00 | 2025 | Apretude |
| Amag Pharmaceuticals, INC. | $124.14 | 2019 | |
| Baxter Healthcare | $94.24 | 2025 | Perclot |
| Hologic Sales and Service, LLC | $94.16 | 2022-2024 | Aptima, Thinprep 2000 Processor |
| Biogen, INC. | $86.45 | 2025 | Zurzuvae |
| Organon LLC | $67.42 | 2022-2025 | Nexplanon |
| Medtronic, INC. | $59.44 | 2022-2023 | V-Loc 180 |
| Teleflex LLC | $41.22 | 2023-2024 | Quikclot |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $30.39 | 2019 | |
| Samsung Hme America, INC. | $30.00 | 2019 | |
| Therapeuticsmd, INC. | $25.47 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $19.72 | 2019 | |
| Shield Therapeutics INC | $15.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rosing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.